oxidopamine has been researched along with Anxiety in 30 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 7.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "Hesperidin treatment was also capable to increase striatal levels of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid and protects against the impairment of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (p < 0." | 5.56 | Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice. ( Antunes, MS; Araújo, SM; Boeira, SP; Bortolotto, VC; Cattelan Souza, L; Ladd, AABL; Ladd, FVL; Moreira, AL; Nogueira, CW; Prigol, M; Silva, MRP, 2020) |
| "Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals." | 3.74 | The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. ( Barker, RA; Kuan, WL; Zhao, JW, 2008) |
| "Hesperidin treatment was also capable to increase striatal levels of dopamine and its metabolite 3,4-dihydroxyphenylacetic acid and protects against the impairment of dopaminergic neurons in the substantia nigra pars compacta (SNpc) (p < 0." | 1.56 | Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice. ( Antunes, MS; Araújo, SM; Boeira, SP; Bortolotto, VC; Cattelan Souza, L; Ladd, AABL; Ladd, FVL; Moreira, AL; Nogueira, CW; Prigol, M; Silva, MRP, 2020) |
| "Anxiety in Parkinson's disease may represent a physiological reaction to the development of other symptoms during disease progression." | 1.51 | Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety. ( Bassani, TB; da Cunha, C; de O Guaita, G; Santiago, RM; Vieira, JCF; Vital, MABF; Zanoveli, JM, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 3 (10.00) | 29.6817 |
| 2010's | 17 (56.67) | 24.3611 |
| 2020's | 7 (23.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zarrindast, MR | 1 |
| Fazli-Tabaei, S | 1 |
| Khakpai, F | 1 |
| Mendes-Pinheiro, B | 1 |
| Soares-Cunha, C | 1 |
| Marote, A | 1 |
| Loureiro-Campos, E | 1 |
| Campos, J | 1 |
| Barata-Antunes, S | 1 |
| Monteiro-Fernandes, D | 1 |
| Santos, D | 1 |
| Duarte-Silva, S | 1 |
| Pinto, L | 1 |
| José Salgado, A | 1 |
| Abrishamdar, M | 1 |
| Farbood, Y | 1 |
| Sarkaki, A | 1 |
| Rashno, M | 1 |
| Badavi, M | 1 |
| Li, R | 1 |
| Wang, Y | 2 |
| Yang, Y | 2 |
| Wu, Z | 1 |
| Wang, L | 1 |
| Tang, G | 1 |
| Yang, J | 1 |
| Liu, J | 4 |
| Cunha, AM | 1 |
| Teixeira, FG | 1 |
| Guimarães, MR | 1 |
| Esteves, M | 1 |
| Pereira-Mendes, J | 1 |
| Soares, AR | 1 |
| Almeida, A | 1 |
| Sousa, N | 1 |
| Salgado, AJ | 1 |
| Leite-Almeida, H | 1 |
| G, A | 1 |
| O, P | 1 |
| E, CM | 1 |
| M, GR | 1 |
| Antunes, MS | 1 |
| Cattelan Souza, L | 1 |
| Ladd, FVL | 1 |
| Ladd, AABL | 1 |
| Moreira, AL | 1 |
| Bortolotto, VC | 1 |
| Silva, MRP | 1 |
| Araújo, SM | 1 |
| Prigol, M | 1 |
| Nogueira, CW | 1 |
| Boeira, SP | 1 |
| Slominsky, PA | 1 |
| Shadrina, MI | 1 |
| Kolomin, TA | 1 |
| Stavrovskaya, AV | 1 |
| Filatova, EV | 1 |
| Andreeva, LA | 1 |
| Illarioshkin, SN | 1 |
| Myasoedov, NF | 1 |
| Sun, YN | 1 |
| Yao, L | 1 |
| Li, LB | 1 |
| Du, CX | 3 |
| Guo, Y | 3 |
| Zhang, QJ | 1 |
| Zhang, J | 2 |
| Lv, SX | 2 |
| Zhang, YM | 1 |
| Loiodice, S | 1 |
| Wing Young, H | 1 |
| Rion, B | 1 |
| Méot, B | 1 |
| Montagne, P | 1 |
| Denibaud, AS | 1 |
| Viel, R | 1 |
| Drieu La Rochelle, C | 1 |
| Ferrazzo, S | 1 |
| Gunduz-Cinar, O | 1 |
| Stefanova, N | 1 |
| Pollack, GA | 1 |
| Holmes, A | 1 |
| Schmuckermair, C | 1 |
| Ferraguti, F | 1 |
| Ogata, M | 1 |
| Akita, H | 1 |
| Ishibashi, H | 1 |
| Vieira, JCF | 1 |
| Bassani, TB | 1 |
| Santiago, RM | 1 |
| de O Guaita, G | 1 |
| Zanoveli, JM | 1 |
| da Cunha, C | 1 |
| Vital, MABF | 1 |
| Feng, CW | 1 |
| Wen, ZH | 1 |
| Huang, SY | 1 |
| Hung, HC | 1 |
| Chen, CH | 1 |
| Yang, SN | 1 |
| Chen, NF | 1 |
| Wang, HM | 1 |
| Hsiao, CD | 1 |
| Chen, WF | 1 |
| Sullivan, RM | 1 |
| Dufresne, MM | 1 |
| Siontas, D | 1 |
| Chehab, S | 1 |
| Townsend, J | 1 |
| Laplante, F | 1 |
| Chiu, WH | 1 |
| Depboylu, C | 1 |
| Hermanns, G | 1 |
| Maurer, L | 1 |
| Windolph, A | 1 |
| Oertel, WH | 1 |
| Ries, V | 1 |
| Höglinger, GU | 1 |
| Silva, TP | 1 |
| Poli, A | 1 |
| Hara, DB | 1 |
| Takahashi, RN | 1 |
| Dallé, E | 1 |
| Daniels, WMU | 1 |
| Mabandla, MV | 1 |
| Picazo, O | 1 |
| Chuc-Meza, E | 1 |
| Anaya-Martinez, V | 1 |
| Jimenez, I | 1 |
| Aceves, J | 1 |
| Garcia-Ramirez, M | 1 |
| Eskow Jaunarajs, KL | 2 |
| Dupre, KB | 1 |
| Ostock, CY | 1 |
| Button, T | 1 |
| Deak, T | 1 |
| Bishop, C | 2 |
| Yan, J | 1 |
| Xu, Y | 1 |
| Zhu, C | 1 |
| Zhang, L | 1 |
| Wu, A | 1 |
| Xiong, Z | 1 |
| Deng, C | 1 |
| Huang, XF | 1 |
| Yenari, MA | 1 |
| Yang, YG | 1 |
| Ying, W | 1 |
| Wang, Q | 1 |
| Furmaga, H | 1 |
| Shah, A | 1 |
| Frazer, A | 1 |
| George, JA | 1 |
| Kuan, WL | 1 |
| Zhao, JW | 1 |
| Barker, RA | 1 |
| Espejo, EF | 2 |
| Miñano, J | 1 |
| Pappas, BA | 1 |
| Murtha, SJ | 1 |
| Park, GA | 1 |
| Condon, KT | 1 |
| Szirtes, RM | 1 |
| Laventure, SI | 1 |
| Ally, A | 1 |
| Steketee, JD | 1 |
| Silverman, PB | 1 |
| Swann, AC | 1 |
30 other studies available for oxidopamine and Anxiety
| Article | Year |
|---|---|
Synergistic effect between quinpirole and L-NAME as well as sulpiride and L-arginine on the modulation of anxiety and memory processes in the 6-OHDA mouse model of Parkinson's disease: An isobologram analysis.
Topics: Adrenergic Agents; Animals; Anxiety; Arginine; Disease Models, Animal; Dopamine Agonists; Dopamine A | 2021 |
Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response.
Topics: Animals; Anxiety; Behavior, Animal; Corpus Striatum; Depressive Disorder; Disease Models, Animal; Fe | 2021 |
Evaluation of betulinic acid effects on pain, memory, anxiety, catalepsy, and oxidative stress in animal model of Parkinson's disease.
Topics: Animals; Antioxidants; Anxiety; Betulinic Acid; Brain-Derived Neurotrophic Factor; Catalepsy; Diseas | 2023 |
The α1 and γ2 subunit-containing GABA
Topics: Animals; Anxiety; Dopamine; Dorsal Raphe Nucleus; gamma-Aminobutyric Acid; Oxidopamine; Parkinson Di | 2023 |
Unilateral accumbal dopamine depletion affects decision-making in a side-specific manner.
Topics: Animals; Anxiety; Behavior, Animal; Decision Making; Depression; Dopaminergic Neurons; Impulsive Beh | 2020 |
Reduction of dopaminergic transmission in the globus pallidus increases anxiety-like behavior without altering motor activity.
Topics: Animals; Anxiety; Brain; Depression; Dopamine; Dopamine Agonists; Globus Pallidus; Male; Motor Activ | 2020 |
Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice.
Topics: Animals; Anxiety; Behavior, Animal; Corpus Striatum; Cytokines; Depression; Dopaminergic Neurons; He | 2020 |
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Disease Models, Animal; Dopaminergic Neurons; Male; O | 2017 |
Activation and blockade of basolateral amygdala 5-HT
Topics: Animals; Anti-Anxiety Agents; Anxiety; Basolateral Nuclear Complex; Corpus Striatum; Dopamine; gamma | 2018 |
Involvement of prelimbic 5-HT
Topics: Animals; Anxiety; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Enzyme Inhibito | 2018 |
Serotonin₆ Receptors in the Prelimbic Cortex are Involved in the Regulation of Anxiety-Like Behaviors in the Rat 6-Hydroxydopamine Parkinson’s Disease Model.
Topics: Animals; Anxiety; Oxidopamine; Parkinson Disease; Rats; Receptors, Serotonin; Serotonin | 2018 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; | 2019 |
Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice.
Topics: Adrenergic Agents; Amygdala; Animals; Anxiety; Catecholamines; Male; Mice; Mice, Inbred C57BL; Oxido | 2019 |
Behavioral responses to anxiogenic tasks in young adult rats with neonatal dopamine depletion.
Topics: Adrenergic Uptake Inhibitors; Animals; Animals, Newborn; Anxiety; Atomoxetine Hydrochloride; Behavio | 2019 |
Anxiety-like behavior induced by 6-OHDA animal model of Parkinson's disease may be related to a dysregulation of neurotransmitter systems in brain areas related to anxiety.
Topics: Adrenergic Agents; Amygdala; Animals; Anxiety; Anxiety Disorders; Behavior, Animal; Brain; Corpus St | 2019 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, An | 2014 |
Mesocortical dopamine depletion and anxiety-related behavior in the rat: sex and hemisphere differences.
Topics: Adrenocorticotropic Hormone; Animals; Anxiety; Dietary Sucrose; Dopamine; Estrous Cycle; Exploratory | 2014 |
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mic | 2015 |
Time course study of microglial and behavioral alterations induced by 6-hydroxydopamine in rats.
Topics: Acetylglucosaminidase; Animals; Anxiety; Behavior, Animal; Biogenic Monoamines; Corpus Striatum; Dep | 2016 |
Anti-parkinsonian effects of fluvoxamine maleate in maternally separated rats.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Antiparkinson Agents; Anxiety; Disease | 2016 |
6-Hydroxydopamine lesion in thalamic reticular nucleus reduces anxiety behaviour in the rat.
Topics: Analysis of Variance; Animals; Anxiety; Cell Count; Exploratory Behavior; Fear; Immunohistochemistry | 2009 |
Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.
Topics: Amygdala; Animals; Anxiety; Behavioral Research; Biogenic Monoamines; Chromatography, High Pressure | 2010 |
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Anxiety; Apoptosis; Autoradiography; Cell Survival; Disease Model | 2011 |
Serotonergic and noradrenergic pathways are required for the anxiolytic-like and antidepressant-like behavioral effects of repeated vagal nerve stimulation in rats.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Adrenergic Uptake Inhibitors; Analysis of Variance; Anim | 2011 |
L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anxiety; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; | 2012 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nerv | 2008 |
Selective dopamine depletion within the medial prefrontal cortex induces anxiogenic-like effects in rats placed on the elevated plus maze.
Topics: Animals; Anxiety; Behavior, Animal; Denervation; Dopamine; Male; Maze Learning; Microinjections; Oxi | 1997 |
Adrenergic hyperactivity and metanephrine excess in the nucleus accumbens after prefrontocortical dopamine depletion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anxiety; Behavior, Animal; Darkness; Dopamine; Epinephrine; | 2001 |
Neonatal brain dopamine depletion and the cortical and behavioral consequences of enriched postweaning environment.
Topics: Animals; Animals, Newborn; Anxiety; Behavior, Animal; Body Weight; Brain Chemistry; Catecholamines; | 1992 |
Noradrenergic receptor mechanisms in neophobia.
Topics: Adenylyl Cyclases; Animals; Anxiety; Behavior, Animal; Clonidine; Colforsin; Dopamine beta-Hydroxyla | 1992 |